New COVID-19 variant defeats plasma treatment, may reduce vaccine efficacy

(Corrects this January 20th story to make clear bioRxiv is a website for research that has yet to be peer-reviewed, not a scientific journal) JOHANNESBURG (Reuters) - The new COVID-19 variant identified in South Africa can evade the antibodies that attack it in treatments using blood plasma from previously recovered patients, and may reduce the efficacy of the current line of vaccines, scientists said on Wednesday. Researchers are racing to establish whether the vaccines currently being rolled out across the globe are effective against the so-called 501Y.V2 variant, identified by South African genomics experts late last year in Nelson Mandela Bay. 'This lineage exhibits complete escape from three classes of therapeutically relevant monoclonal antibodies,' the team of scientists from three South African universities working with the National Institute for Communicable Diseases (NICD) wrote in a paper in bioRxiv, a website that publishes scientific research prior to its being peer-reviewed and submitted to journals

Reuters January 23, 2021 00:11:24 IST
New COVID-19 variant defeats plasma treatment, may reduce vaccine efficacy

COVID-19 variant defeats plasma treatment, may reduce vaccine efficacy" src="https://images.firstpost.com/wp-content/themes/firstpost/images/220x220_Watermark.jpg" alt="New COVID19 variant defeats plasma treatment may reduce vaccine efficacy" width="300" height="225" />

(Corrects this January 20th story to make clear bioRxiv is a website for research that has yet to be peer-reviewed, not a scientific journal)

JOHANNESBURG (Reuters) - The new COVID-19 variant identified in South Africa can evade the antibodies that attack it in treatments using blood plasma from previously recovered patients, and may reduce the efficacy of the current line of vaccines, scientists said on Wednesday.

Researchers are racing to establish whether the vaccines currently being rolled out across the globe are effective against the so-called 501Y.V2 variant, identified by South African genomics experts late last year in Nelson Mandela Bay.

"This lineage exhibits complete escape from three classes of therapeutically relevant monoclonal antibodies," the team of scientists from three South African universities working with the National Institute for Communicable Diseases (NICD) wrote in a paper in bioRxiv, a website that publishes scientific research prior to its being peer-reviewed and submitted to journals.

"Furthermore, 501Y.V2 shows substantial or complete escape from neutralising antibodies in COVID-19 convalescent plasma," they wrote, adding that their conclusions "highlight the prospect of reinfection ... and may foreshadow reduced efficacy of current spike-based vaccines."

The 501Y.V2 variant is 50% more infectious than previous ones, South African researchers said this week. It has already spread to at least 20 countries since being reported to the World Health Organisation in late December.

It is one of several new variants discovered in recent months, including others first found in England and Brazil.

The variant is the main driver of South Africa's second wave of COVID-19 infections, which hit a new daily peak above 21,000 cases earlier this month, far above the first wave, before falling to about 12,000 a day.

Convalescent blood plasma from previous patients has not been shown to be effective when administered to severely ill patients requiring intensive care for COVID-19 , but it is approved in several countries as an emergency measure.

British scientists and politicians have expressed concern that vaccines currently being deployed or in development could be less effective against the variant.

The paper said it remained to be seen how effective current vaccines were against 501Y.V2, which would only be determined by large-scale clinical trials. But results showed the need for new vaccines to be designed to tackle the evolving threat, it said.

(Reporting by Tim Cocks; Editing by Peter Graff)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Subscribe to Moneycontrol Pro at ₹499 for the first year. Use code PRO499. Limited period offer. *T&C apply

also read

Thyssenkrupp ends talks with UK's Liberty on steel unit sale
Business

Thyssenkrupp ends talks with UK's Liberty on steel unit sale

By Christoph Steitz, Tom Käckenhoff and Arno Schuetze FRANKFURT (Reuters) - German conglomerate Thyssenkrupp ended talks to sell its steel division to Britain's Liberty Steel due to differences over value, the latest setback in efforts to consolidate the European sector. Liberty Steel, led by commodities tycoon Sanjeev Gupta, last month submitted a firmed-up non-binding bid for Thyssenkrupp's steel unit, Europe's second biggest in terms of sales, which sources said included commitments to protect jobs and sites.

Factbox: Stonks in Washington: Deciphering Reddit's WallStreetBets lingo
Business

Factbox: Stonks in Washington: Deciphering Reddit's WallStreetBets lingo

(Reuters) - Reddit trading lingo may filter in to Washington on Thursday when top hedge fund managers, the head of Robinhood and Roaring Kitty himself are set to give testimony before U.S. House of Representatives lawmakers.

Brent gives up gains after rising above $65 on Texas freeze
Business

Brent gives up gains after rising above $65 on Texas freeze

By Stephanie Kelly NEW YORK (Reuters) - Oil prices steadied on Thursday, with Brent edging back from a 13-month high, after a sharp drop in U.S. crude inventories supported prices, while buying spurred by a cold snap in the largest U.S. energy-producing state petered out.